Cour Pharmaceutics

Cour Pharmaceutics

Headquarter
Skokie, IL - United States

Milestones
Founded: 2012
Invested: 2023

Founders / CEO
John J. Puisis, CEO

Vertical
Biotech

Board Participation
Paolo di Giorgio, Board Member

Website

Linkedin

 

 

Developer of an immune-modifying platform intended to achieve antigen specific tolerance for immune-mediated disease. The company's platform offers non-biological therapeutics for acute inflammation, autoimmunity, and allergic conditions and also engages in pharmaceutical development of immunology, pathology, or cardiovascular medicinal products, enabling patients to get acute treatments for encephalitis syndromes, autoimmune disorders, infections and heart attacks.

 

Related news:

Angelini Ventures joins $105 Million Series A financing for COUR Pharmaceuticals to advance its antigen-specific immune tolerance platform